GUILFORD, Conn. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today announced it received a grant in the amount of $5 million from the Bill & Melinda Gates Foundation to improve maternal and fetal health. Through this grant Butterfly will provide 1,000 healthcare workers in Sub-Saharan Africa with Butterfly iQ+, the world’s only handheld, whole-body point-of-care ultrasound probe.
Complications of pregnancy represent some of the largest contributors of morbidity and mortality in resource constrained care settings. Butterfly will bring 1,000 Butterfly iQ+ probes to Sub-Saharan Africa to improve community access to medical imaging. As part of this initiative, 500 probes will be given to mid-level practitioners in Kenya and 500 will be distributed to healthcare workers in South Africa; both distributions will focus on improving maternal and fetal health.
“Many places in the world, especially low- and middle-income countries, are diagnostic deserts, leaving practitioners with virtually no imaging modalities to aid in the diagnosis and subsequent treatment of patients,” said Dr. Todd Fruchterman, President and CEO, Butterfly Network. “At Butterfly, we’ve long envisioned and innovated for the next generation of point-of-care. With this grant, we take another important step toward improving worldwide access to medical imaging and will also demonstrate how mid-level practitioners can meaningfully enhance care for pregnant women and their unborn infants.”
“For years, the Gates Foundation has supported Butterfly’s efforts to improve healthcare in the places where it’s most needed,” said Darius Shahida, Chief Strategy and Business Development Officer at Butterfly Network. “This new grant represents an important step toward that goal in its potential to signal the transformational impact of Butterfly’s technology in some of the most remote settings.”
Butterfly Network will document best practices for point-of-care ultrasound utilization that can be leveraged to optimize the qualitative and quantitative clinical and economic impact of Butterfly iQ+ deployments across other care settings. Additionally, a portion of this grant will also be used to accelerate the launch of new maternal and fetal health capabilities available within the Butterfly iQ+ mobile application.
To learn more about the impact of Butterfly technology and to view a demo of Butterfly iQ+, visit: https://www.butterflynetwork.com.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased online today by healthcare practitioners in the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.
Butterfly iQ+ is a prescription device intended for trained healthcare professionals only.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to financial results, future performance, development of products and services, and the size and potential growth of current or future markets for its products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business, including issues relating to Omicron or other variants; the ability to recognize the anticipated benefits of the business combination; the Company’s ability to grow and manage growth profitably; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; manufacturing and supply of the Company’s products; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using its products and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s ability to raise financing in the future; and other risks and uncertainties indicated from time to time in the Company’s most recent Annual Report on Form 10-K or in subsequent filings that it makes with the Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. The Company does not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.